在接受二线化疗后,对敏感的复发性上皮卵巢癌患者进行维持化疗
Yen-Fu Chen1, Shih-Tien Hsu1,2,3, Sheau-Feng Hwang1,4
1Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
Journal of clinical medicine
|January 23, 2024
概括
维护化疗对白金敏感的复发性卵巢癌患者有希望,在二线治疗后部分反应,显著改善无进展生存率 (PFS). 对于特定的患者群体需要进一步的研究.
科学领域:
- 妇科 妇科 妇科 妇科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 评估对敏感性复发性上皮卵巢癌的维持化疗.
- 评估二线化疗后的疗效和副作用.
研究的目的:
- 确定维护化疗在敏感性复发性卵巢癌中的作用.
- 为了比较标准化疗和维持化疗组之间的生存结果.
主要方法:
- 一个单一研究所对72名白金敏感性复发性卵巢癌患者的研究.
- 在二线化疗后实现完全或部分反应的患者被分为标准 (≤6周期) 和维持 (>6周期) 组.
- 患者特征和生存结果的比较.
主要成果:
- 总的来说,维持化疗显示出更糟糕的生存结果.
- 在部分反应的患者中 (没有先前的手术/放射治疗),维持化疗显著改善了无进展生存期 (PFS) (中位数3.6与6.7个月;p = 0.007).
- 没有观察到总生存时间 (OS) 的显著改善;中位维持周期为四个.
结论:
- 维护化疗可能有利于敏感性复发性卵巢癌的选定患者.
- 特别是,实现部分反应的患者可能会从维持治疗中受益.
- 对特定患者亚组进行进一步调查是有必要的.
更多相关视频
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
205
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
205
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


